We had 5 months of declining deaths after vaccines. After all, the proportion who were unvaccinated & susceptible existed during these months as well. But delta was just settling in
Once delta established itself, we are at >2000 deaths/day.
Whatever protection we had against original strain of Covid, disappeared with delta. delta was more transmissible. Taking off masks too early didn't help.
Deaths are very high with delta, but we would have faced a much bigger crisis without vaccines.
Based on Israel study on effect of vaccines in reducing deaths and hospitalizations, and knowing what happened in India, we probably saved >100,000 lives in the US because of vaccinations. thelancet.com/journals/lanin…
Our greatest worry should be the rise of a new variant.
Here is @kenjeong explaining so clearly what I'm struggling to say, which is that we were surprised by the delta variant, and how delta changed everything.
The FDA seems to have been more lenient on who should get the booster dose than the CDC panel. How's is that going to play out?
Unlike the FDA, the CDC panel has not recommended a booster for those at high risk of occupational exposure. Something that an FDA advisory panel unanimously voted to recommend to the FDA. And the FDA obliged.
So we have an FDA approved EUA indication that is not recommended by the CDC panel.
Unless CDC director revises it, I think it will be interesting how this plays out for healthcare workers and teachers.
Somewhere in the last few days Mississippi became only the second state (after Florida) to average more daily deaths from COVID than all previous waves.
Only 43% are fully vaccinated in Mississippi.
It's pretty hard to exceed peaks set prior to arrival of vaccines. It's a cause for concern. Louisiana and Georgia are nearing this level and I hope rates in those states goes down soon.
CASSIOPEIA trial maintenance results in myeloma: Main takeaway is that daratumumab maintenance provided ZERO benefit if daratumumab was given as induction/consolidation
This PFS curve (blue versus yellow line) should have been in the main paper, not the Appendix. @TheLancetOncol
Key points
1) When this trial was designed we were already using lenalidomide maintenance as standard. This trial had a no treatment control arm. So the question is how good is Dara maintenance against Len. Not Dara maintenance against nothing.
2) If 6 cycles of Dara given upfront provides the same as many years of Dara maintenance, it is preferable to give the Dara at induction. Not as maintenance.
The myeloma field is moving in this direction giving Dara upfront.
Two doses of J&J vaccine provide outstanding protection against COVID. Wish J&J vaccine had always been a two dose approach from the outset , from when they designed the phase III trial. cnn.com/2021/09/21/hea…